# Phase 1/2 Burkitt Lymphoma trials recruiting: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 1/2 for Burkitt Lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Burkitt Lymphoma trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/burkitt-lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| August 18, 2026 | NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | BeOne Medicines | Phase 1/2 | Not yet recruiting | Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770698) |
| May 8, 2026 | NCT07575971 | Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute... | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575971) |
| May 8, 2026 | NCT07575919 | Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575919) |
| April 13, 2026 | NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies | Beijing Biotech | Phase 1/2 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523555) |
| January 2, 2026 | NCT07313852 | A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Not yet recruiting | B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07313852) |
| August 7, 2025 | NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | AstraZeneca | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109219) |
| July 17, 2025 | NCT07069699 | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07069699) |
| June 13, 2025 | NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children... | Princess Maxima Center for Pediatric Oncology | Phase 1/2 | Not yet recruiting | Leukemia, Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020260) |
| December 16, 2024 | NCT06735495 | CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1/2 | Recruiting | B-Cell Lymphoblastic Leukemia/Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735495) |
| October 10, 2024 | NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | Kara Yakhteh Tajhiz Azma Company | Phase 1/2 | Recruiting | Relapse/Refractory B-cell Acute Lymphoblastic Leukemia | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06635330) |
| August 30, 2024 | NCT06580301 | Study of YK012 in B-cell Acute Lymphoblastic Leukemia | Excyte Biopharma Ltd | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06580301) |
| August 1, 2024 | NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Vironexis Biotherapeutics Inc. | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533579) |
| May 1, 2024 | NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395103) |
| March 1, 2024 | NCT06287229 | Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With... | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06287229) |
| November 18, 2023 | NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | AstraZeneca | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL) | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06137118) |
| January 6, 2023 | NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05674175) |
| December 28, 2022 | NCT05667506 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | Juventas Cell Therapy Ltd. | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05667506) |
| July 29, 2022 | NCT05480449 | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05480449) |
| July 5, 2022 | NCT05442515 | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, B-precursor ALL, B-All... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05442515) |
| April 5, 2022 | NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic... | Assistance Publique - Hôpitaux de Paris | Phase 1/2 | Recruiting | B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05310591) |
| September 10, 2020 | NCT04544592 | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | University of Colorado, Denver | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04544592) |
| July 29, 2020 | NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | New York Medical College | Phase 1/2 | Recruiting | B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04491370) |
| July 21, 2017 | NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03223610) |
| June 13, 2011 | NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia... | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01371630) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 3 |
| M.D. Anderson Cancer Center | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| University of Colorado, Denver | 1 |
| Princess Maxima Center for Pediatric Oncology | 1 |
| Vironexis Biotherapeutics Inc. | 1 |
| New York Medical College | 1 |
| Juventas Cell Therapy Ltd. | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| Hospital Universitario Dr. Jose E. Gonzalez | 1 |
| Excyte Biopharma Ltd | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Kara Yakhteh Tajhiz Azma Company | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 8 |
| Australia | 3 |
| Canada | 3 |
| France | 3 |
| South Korea | 3 |
| Spain | 3 |
| Taiwan | 3 |
| United Kingdom | 3 |
| Brazil | 2 |
| Germany | 2 |
| Italy | 2 |
| Netherlands | 2 |
| Japan | 2 |
| Belgium | 1 |
| Chile | 1 |
| Colombia | 1 |
| Czechia | 1 |
| Denmark | 1 |
| Greece | 1 |
| Hungary | 1 |
| Israel | 1 |
| Slovakia | 1 |
| Sweden | 1 |
| Turkey (Türkiye) | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lebanese restaurants in the United States](https://specstream.ai/data/businesses/lebanese-restaurants/united-states)
- [Gerontology practices in the United States](https://specstream.ai/data/businesses/gerontology-practices/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
- [Ambulance services in the United States](https://specstream.ai/data/businesses/ambulance-services/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
